Abstract. Most bladder cancers are poorly responsive to immune checkpoint blockade (ICB). With the need to define mechanisms of de novo resistance, including contributions from the tumor ...
1Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 2Division of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, ...
1Bioray Pharmaceutical Corp., San Diego, CA.
Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing, China.
Cancer Res (2023) 83 (8_Supplement): LB031.
1Department of Oncology, University of Lausanne, Lausanne, Switzerland.
Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, ...
1Houston Methodist Neal Cancer Center, Houston, TX.
1Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York. 2Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
1Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York.
1Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback